436 related articles for article (PubMed ID: 27197290)
21. Independent Validation of a Tissue Systems Pathology Assay to Predict Future Progression in Nondysplastic Barrett's Esophagus: A Spatial-Temporal Analysis.
Frei NF; Konte K; Bossart EA; Stebbins K; Zhang Y; Pouw RE; Critchley-Thorne RJ; Bergman JJGHM
Clin Transl Gastroenterol; 2020 Oct; 11(10):e00244. PubMed ID: 33108124
[TBL] [Abstract][Full Text] [Related]
22. Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma.
Goodarzi M; Correa AM; Ajani JA; Swisher SG; Hofstetter WL; Guha S; Deavers MT; Rashid A; Maru DM
Mod Pathol; 2009 Dec; 22(12):1612-21. PubMed ID: 19734842
[TBL] [Abstract][Full Text] [Related]
23. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression.
Skacel M; Petras RE; Gramlich TL; Sigel JE; Richter JE; Goldblum JR
Am J Gastroenterol; 2000 Dec; 95(12):3383-7. PubMed ID: 11151865
[TBL] [Abstract][Full Text] [Related]
24. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up.
Sharma P; Morales TG; Bhattacharyya A; Garewal HS; Sampliner RE
Am J Gastroenterol; 1997 Nov; 92(11):2012-6. PubMed ID: 9362182
[TBL] [Abstract][Full Text] [Related]
25. Autofluorescence endoscopy in surveillance of Barrett's esophagus: a multicenter randomized trial on diagnostic efficacy.
Borovicka J; Fischer J; Neuweiler J; Netzer P; Gschossmann J; Ehmann T; Bauerfeind P; Dorta G; Zürcher U; Binek J; Meyenberger C
Endoscopy; 2006 Sep; 38(9):867-72. PubMed ID: 16981102
[TBL] [Abstract][Full Text] [Related]
26. Usefulness of insulin-like growth factor II mRNA-binding protein 3 (IMP3) as a new marker for the diagnosis of esophageal adenocarcinoma in challenging cases.
Kazeminezhad B; Mirafsharieh SA; Dinyari K; Azizi D; Ebrahimi A
Turk J Gastroenterol; 2014 Jun; 25(3):253-6. PubMed ID: 25141312
[TBL] [Abstract][Full Text] [Related]
27. Validation of a biomarker panel in Barrett's esophagus to predict progression to esophageal adenocarcinoma.
Eluri S; Klaver E; Duits LC; Jackson SA; Bergman JJ; Shaheen NJ
Dis Esophagus; 2018 Nov; 31(11):. PubMed ID: 29635420
[TBL] [Abstract][Full Text] [Related]
28. Long-term follow-up of Barrett's high-grade dysplasia.
Weston AP; Sharma P; Topalovski M; Richards R; Cherian R; Dixon A
Am J Gastroenterol; 2000 Aug; 95(8):1888-93. PubMed ID: 10950031
[TBL] [Abstract][Full Text] [Related]
29. Pathology of Barrett's esophagus by proton magnetic resonance spectroscopy and a statistical classification strategy.
Doran ST; Falk GL; Somorjai RL; Lean CL; Himmelreich U; Philips J; Russell P; Dolenko B; Nikulin AE; Mountford CE
Am J Surg; 2003 Mar; 185(3):232-8. PubMed ID: 12620562
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry.
Ramel S; Reid BJ; Sanchez CA; Blount PL; Levine DS; Neshat K; Haggitt RC; Dean PJ; Thor K; Rabinovitch PS
Gastroenterology; 1992 Apr; 102(4 Pt 1):1220-8. PubMed ID: 1551529
[TBL] [Abstract][Full Text] [Related]
31. Population-based study reveals new risk-stratification biomarker panel for Barrett's esophagus.
Bird-Lieberman EL; Dunn JM; Coleman HG; Lao-Sirieix P; Oukrif D; Moore CE; Varghese S; Johnston BT; Arthur K; McManus DT; Novelli MR; O'Donovan M; Cardwell CR; Lovat LB; Murray LJ; Fitzgerald RC
Gastroenterology; 2012 Oct; 143(4):927-35.e3. PubMed ID: 22771507
[TBL] [Abstract][Full Text] [Related]
32. Diagnosis and Management of Low-Grade Dysplasia in Barrett's Esophagus: Expert Review From the Clinical Practice Updates Committee of the American Gastroenterological Association.
Wani S; Rubenstein JH; Vieth M; Bergman J
Gastroenterology; 2016 Nov; 151(5):822-835. PubMed ID: 27702561
[TBL] [Abstract][Full Text] [Related]
33. Increasing diagnostic accuracy to grade dysplasia in Barrett's esophagus using an immunohistochemical panel for CDX2, p120ctn, c-Myc and Jagged1.
Karamchandani DM; Lehman HL; Ohanessian SE; Massé J; Welsh PA; Odze RD; Goldblum JR; Berg AS; Stairs DB
Diagn Pathol; 2016 Feb; 11():23. PubMed ID: 26926447
[TBL] [Abstract][Full Text] [Related]
34. Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features.
Sato F; Jin Z; Schulmann K; Wang J; Greenwald BD; Ito T; Kan T; Hamilton JP; Yang J; Paun B; David S; Olaru A; Cheng Y; Mori Y; Abraham JM; Yfantis HG; Wu TT; Fredericksen MB; Wang KK; Canto M; Romero Y; Feng Z; Meltzer SJ
PLoS One; 2008 Apr; 3(4):e1890. PubMed ID: 18382671
[TBL] [Abstract][Full Text] [Related]
35. Aberrant p53 Immunostaining in Barrett's Esophagus Predicts Neoplastic Progression: Systematic Review and Meta-Analyses.
Snyder P; Dunbar K; Cipher DJ; Souza RF; Spechler SJ; Konda VJA
Dig Dis Sci; 2019 May; 64(5):1089-1097. PubMed ID: 30911864
[TBL] [Abstract][Full Text] [Related]
36. CEACAM 6, a novel marker for the diagnosis of Barrett's esophagus.
Sharma N; Srivastava S; Kern F; Xian W; Yeoh KG; Ming T; McKeon F; Ho KY
Dis Esophagus; 2017 Jul; 30(7):1-5. PubMed ID: 28475729
[TBL] [Abstract][Full Text] [Related]
37. Predicting Progression in Barrett's Esophagus: Development and Validation of the Barrett's Esophagus Assessment of Risk Score (BEAR Score).
Brown CS; Lapin B; Goldstein JL; Linn JG; Talamonti MS; Carbray J; Ujiki MB
Ann Surg; 2018 Apr; 267(4):716-720. PubMed ID: 28230661
[TBL] [Abstract][Full Text] [Related]
38. Predictors of dysplastic and neoplastic progression of Barrett’s esophagus.
Alnasser S; Agnihotram R; Martel M; Mayrand S; Franco E; Ferri L
Can J Surg; 2019 Apr; 62(2):93-99. PubMed ID: 30907564
[TBL] [Abstract][Full Text] [Related]
39. Methylene blue staining of dysplastic and nondysplastic Barrett's esophagus: an in vivo and ex vivo study.
Canto MI; Setrakian S; Willis JE; Chak A; Petras RE; Sivak MV
Endoscopy; 2001 May; 33(5):391-400. PubMed ID: 11396755
[TBL] [Abstract][Full Text] [Related]
40. Abnormal TP53 Predicts Risk of Progression in Patients With Barrett's Esophagus Regardless of a Diagnosis of Dysplasia.
Redston M; Noffsinger A; Kim A; Akarca FG; Rara M; Stapleton D; Nowden L; Lash R; Bass AJ; Stachler MD
Gastroenterology; 2022 Feb; 162(2):468-481. PubMed ID: 34757142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]